TORRENT PHARMACEUTICALS LTD. - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Download	< Back
24 Jan 2023
This is with respect to our earlier communication on September 28, 2022 regarding the USFDA inspection at our manufacturing facility at Indrad, Gujarat and issuance of Form 483 by USFDA with 3 observations. We now wish to inform that the Company has received a communication from the USFDA determining the inspection classification as 'Official Action Indicated' (OAI). This inspection classification will not have impact on existing supplies or revenues from this facility. Torrent Pharma continues to cooperate with the USFDA and will undertake all necessary remedial steps to resolve these issues to the satisfaction of the regulator. Torrent Pharma remains committed to being cGMP compliant quality standards across all its facilities. Please take the information on record.
View all announcements for TORRENT PHARMACEUTICALS LTD.	Source: BSE India

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2022	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us

Mutual Fund Selector